Basic Information
| RNALocate ID: | RLID:11001835 |
| RNA Symbol: | hsa-miR-191-5p |
| Localization: | Exosome |
RNA Information
| RNA Name: | hsa-miR-191 |
| RNA ID: | miRBase:MIMAT0000440 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 20976003 |
| Tissue/Cell Line: | Breast cancer cell line (MCF-7) |
| Method: | Microarray |
| Description: | Because of the suggested roles of extracellular miRNAs in signaling and diagnosis, we investigated whether the intracellular and extracellular miRNA composition are the same. To answer this question, we performed microRNA microarray analyses of MCF7 cellular (c) and extracellular (x) RNAs (Figure 2A), and found that about 66% of the released miRNAs are at an abundance that closely reflects the cellular miRNA abundance (Figures 2B and 2C). This finding is in agreement with a model wherein most, but not all miRNAs are released passively by mass action. Data are collected from Figure 2. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001799 | Cytoplasm | Cell line (HeLa) | 21695135 |
| RLID:01001800 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001801 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:01001802 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
| RLID:01001803 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001804 | Nucleolus | HeLa cells | 23940654 |
| RLID:01001805 | Nucleolus | Breast adenocarcinoma cells (MCF-7) | 24918059 |
| RLID:11001832 | Apoptotic body | Human umbilical vein endothelial cells | 19996457 |
| RLID:11001833 | Exosome | Human cervical cancer cell line (HeLa) | 25760330 |
| RLID:11001834 | Exosome | Plasma | 19289371 |
| RLID:11001836 | Exosome | B cell line (Raji)|Jurkat-derived T cell line (J77cl20) | 21505438 |
| RLID:11001837 | Exosome | Breast milk | 22211110 |
| RLID:11001838 | Exosome | Brain tissue | 23382797 |
| RLID:11001839 | Exosome | Plasma | 23663360 |
| RLID:11001840 | Exosome | Human mast cell line (HMC-1) | 24009880 |
| RLID:11001841 | Exosome | Serum|Urine | 25135963 |
| RLID:11001842 | Extracellular vesicle | HEK-293T cells | 22849433 |
| RLID:11001843 | Microvesicle | Plasma | 23077538 |
| RLID:11001844 | Microvesicle | Seminal plasma | 23539611 |
| RLID:11001845 | Microvesicle | Follicular fluid | 23666971 |
| RLID:11001846 | Microvesicle | Hepatoma cells | 23771658 |
| RLID-D:11000088 | Exosome | Blood|B lymphoblastoid cells|Breast milk|Colon tissue|Endothelial cells|Epithelial cells|Kidney tissue|Lymphoma tissue|Mast cells|Seminal fluid|Tongue tissue | |
| RLID-D:11000368 | Microvesicle | Blood|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-191-5p | Splenic marginal zone lymphoma | MNDR-E-MI-22530 |
| MNDR | hsa-miR-191-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-22531 |
| MNDR | hsa-miR-191-5p | Oral squamous cell carcinoma | MNDR-E-MI-22532 |
| MNDR | hsa-miR-191-5p | Medulloblastoma | MNDR-E-MI-22533 |
| MNDR | hsa-miR-191-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-22534 |
| MNDR | hsa-miR-191-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-22535 |
| MNDR | hsa-miR-191-5p | Lymphoma | MNDR-E-MI-22536 |
| MNDR | hsa-miR-191-5p | Lymphoma non-hodgkin | MNDR-E-MI-22537 |
| MNDR | hsa-miR-191-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-22538 |
| MNDR | hsa-miR-191-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-22539 |
| MNDR | hsa-miR-191-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-22540 |
| MNDR | hsa-miR-191-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-22541 |
| MNDR | hsa-miR-191-5p | Breast cancer luminal | MNDR-E-MI-22542 |
| MNDR | hsa-miR-191-5p | Niemann-pick disease type c | MNDR-E-MI-22543 |
| MNDR | hsa-miR-191-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-22544 |
| MNDR | hsa-miR-191-5p | Prostate cancer | MNDR-E-MI-22545 |
| MNDR | hsa-miR-191-5p | Gastric cancer | MNDR-E-MI-22546 |
| MNDR | hsa-miR-191-5p | Alzheimer disease | MNDR-E-MI-22547 |
| MNDR | hsa-miR-191-5p | Dysautonomia familial | MNDR-E-MI-22548 |
| MNDR | hsa-miR-191-5p | Myotonic dystrophy | MNDR-E-MI-22549 |
| MNDR | hsa-miR-191-5p | Head and neck cancer | MNDR-E-MI-22550 |
| MNDR | hsa-miR-191-5p | Graves disease | MNDR-E-MI-22551 |
| MNDR | hsa-miR-191-5p | Cardiovascular disease | MNDR-E-MI-22552 |
| MNDR | hsa-miR-191-5p | Carotid stenosis | MNDR-E-MI-22553 |
| MNDR | hsa-miR-191-5p | Lung cancer | MNDR-E-MI-22554 |
| MNDR | hsa-miR-191-5p | Down syndrome | MNDR-E-MI-22555 |
| MNDR | hsa-miR-191-5p | Parkinson disease | MNDR-E-MI-22556 |
| MNDR | hsa-miR-191-5p | Niemann-pick disease | MNDR-E-MI-22557 |
| MNDR | hsa-miR-191-5p | Cognitive dysfunction | MNDR-E-MI-22558 |
| MNDR | hsa-miR-191-5p | Breast cancer | MNDR-E-MI-22559 |
| MNDR | hsa-miR-191-5p | Pituitary neoplasms | MNDR-E-MI-22560 |
| MNDR | hsa-miR-191-5p | Pancreatic cancer | MNDR-E-MI-22561 |
| MNDR | hsa-miR-191-5p | Melanoma | MNDR-E-MI-22562 |
| MNDR | hsa-miR-191-5p | Lesch-nyhan syndrome | MNDR-E-MI-22563 |
| MNDR | hsa-miR-191-5p | Colon cancer | MNDR-E-MI-22564 |
| MNDR | hsa-miR-191-5p | Ischemic attack transient | MNDR-E-MI-22565 |
| MNDR | hsa-miR-191-5p | Colon adenocarcinoma | MNDR-E-MI-22566 |
| MNDR | hsa-miR-191-5p | Multiple sclerosis | MNDR-E-MI-22567 |
| MNDR | hsa-miR-191-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-22568 |
| MNDR | hsa-miR-191-5p | Familial ovarian cancer | MNDR-E-MI-22569 |
| MNDR | hsa-miR-191-5p | Prostate adenocarcinoma | MNDR-E-MI-22570 |
| MNDR | hsa-miR-191-5p | Kidney cancer | MNDR-E-MI-22571 |
| MNDR | hsa-miR-191-5p | Carcinoma ductal breast | MNDR-E-MI-22572 |
| MNDR | hsa-miR-191-5p | Invasive ductal carcinoma | MNDR-E-MI-22573 |
| MNDR | hsa-miR-191-5p | Glioblastoma | MNDR-E-MI-22574 |
| MNDR | hsa-miR-191-5p | Glioma | MNDR-E-MI-22575 |
| MNDR | hsa-miR-191-5p | Chronic obstructive pulmonary disease | MNDR-E-MI-22576 |
| MNDR | hsa-miR-191-5p | Chordoma | MNDR-E-MI-22577 |
| MNDR | hsa-miR-191-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-22578 |
| MNDR | hsa-miR-191-5p | Osteosarcoma | MNDR-E-MI-22579 |
| MNDR | hsa-miR-191-5p | Meningioma | MNDR-E-MI-22580 |
| MNDR | hsa-miR-191-5p | Liver cancer | MNDR-E-MI-22581 |
| MNDR | hsa-miR-191-5p | Cervical adenocarcinoma | MNDR-E-MI-22582 |
| MNDR | hsa-miR-191-5p | Gastric adenocarcinoma | MNDR-E-MI-22583 |
| MNDR | hsa-miR-191-5p | Pituitary adenoma | MNDR-E-MI-22584 |
| MNDR | hsa-miR-191-5p | Lung squamous cell carcinoma | MNDR-E-MI-22585 |
| MNDR | hsa-miR-191-5p | Lung adenocarcinoma | MNDR-E-MI-22586 |
| MNDR | hsa-miR-191-5p | Thyroid carcinoma | MNDR-E-MI-22587 |
| MNDR | hsa-miR-191-5p | Ovarian carcinoma | MNDR-E-MI-22588 |
| MNDR | hsa-miR-191-5p | Bladder urothelial carcinoma | MNDR-E-MI-22589 |
| MNDR | hsa-miR-191-5p | Pancreatic adenocarcinoma | MNDR-E-MI-22590 |
| MNDR | hsa-miR-191-5p | Carcinoma renal cell | MNDR-E-MI-22591 |
| MNDR | hsa-miR-191-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-22592 |
| MNDR | hsa-miR-191-5p | Renal clear cell carcinoma | MNDR-E-MI-22593 |
| MNDR | hsa-miR-191-5p | Biliary tract cancer | MNDR-E-MI-22594 |
| MNDR | hsa-miR-191-5p | Cholangiocarcinoma | MNDR-E-MI-22595 |
| MNDR | hsa-miR-191-5p | Esophageal cancer | MNDR-E-MI-22596 |
| MNDR | hsa-miR-191-5p | Lung small cell carcinoma | MNDR-E-MI-22597 |
| MNDR | hsa-miR-191-5p | Encephalopathy bovine spongiform | MNDR-E-MI-22598 |
| MNDR | hsa-miR-191-5p | Synovial sarcoma | MNDR-E-MI-22599 |
| MNDR | hsa-miR-191-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-22600 |
| MNDR | hsa-miR-191-5p | Myocardial infarction | MNDR-E-MI-22601 |
| MNDR | hsa-miR-191-5p | Encephalomyelitis | MNDR-E-MI-22602 |
| MNDR | hsa-miR-191-5p | Adenoma | MNDR-E-MI-22603 |
| MNDR | hsa-miR-191-5p | Breast invasive carcinoma | MNDR-E-MI-22604 |
| MNDR | hsa-miR-191-5p | Hepatocellular carcinoma | MNDR-E-MI-22605 |
| MNDR | hsa-miR-191-5p | Familiar ovarian carcinoma | MNDR-E-MI-22606 |
| MNDR | hsa-miR-191-5p | B-cell lymphoma | MNDR-E-MI-22607 |
| MNDR | hsa-miR-191-5p | Rheumatoid arthritis | MNDR-E-MI-22608 |
| MNDR | hsa-miR-191-5p | Retinoblastoma | MNDR-E-MI-22609 |
| MNDR | hsa-miR-191-5p | Barrett's adenocarcinoma | MNDR-E-MI-22610 |
| MNDR | hsa-miR-191-5p | Chronic fatigue syndrome | MNDR-E-MI-22611 |
| MNDR | hsa-miR-191-5p | Burkitt lymphoma | MNDR-E-MI-22612 |
| MNDR | hsa-miR-191-5p | Neuromyelitis optica | MNDR-E-MI-22613 |
| MNDR | hsa-miR-191-5p | Colorectal cancer | MNDR-E-MI-22614 |
| MNDR | hsa-miR-191-5p | Nasopharynx carcinoma | MNDR-E-MI-22615 |
| MNDR | hsa-miR-191-5p | Type 2 diabetes mellitus | MNDR-E-MI-22616 |
| MNDR | hsa-miR-191-5p | Multiple myeloma | MNDR-E-MI-22617 |
| MNDR | hsa-miR-191-5p | Acute lymphocytic leukemia | MNDR-E-MI-22618 |
| MNDR | hsa-miR-191-5p | Brain injuries traumatic | MNDR-E-MI-22619 |
| MNDR | hsa-miR-191-5p | Ependymoma | MNDR-E-MI-22620 |
| MNDR | hsa-miR-191-5p | Nasopharyngeal cancer | MNDR-E-MI-22621 |
| MNDR | hsa-miR-191-5p | Prostatic neoplasms | MNDR-E-MI-22622 |
| MNDR | hsa-miR-191-5p | Sleep deprivation | MNDR-E-MI-22623 |
| MNDR | hsa-miR-191-5p | Epstein-barr virus infections | MNDR-E-MI-22624 |
| MNDR | hsa-miR-191-5p | Intracranial hemorrhage hypertensive | MNDR-E-MI-22625 |
| MNDR | hsa-miR-191-5p | Venous thromboembolism | MNDR-E-MI-22626 |
| MNDR | hsa-miR-191-5p | Stroke lacunar | MNDR-E-MI-22627 |
| MNDR | hsa-miR-191-5p | Barrett's carcinogenesis | MNDR-E-MI-22628 |
| MNDR | hsa-miR-191-5p | Breast cancer her3+ negative | MNDR-E-MI-22629 |
| MNDR | hsa-miR-191-5p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-22630 |
| MNDR | hsa-miR-191-5p | Tubulovillous adenoma | MNDR-E-MI-22631 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | BASP1 | Homo sapiens | RR00211911 |
TOP